ArticleJournal of cachexia, sarcopenia and muscle2014
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014.
Article in Journal of cachexia, sarcopenia and muscle, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 215 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
215 citing papers in PubMed, 5 syntheses or guidelines pooled it, 388 citations in OpenAlex.
- Are sarcopenia and its individual components linked to all-cause mortality in heart failure? A systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Pooled it
- Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients.Aging · 2024Pooled it
- The Effect of Cannabis-Based Medicine in the Treatment of Cachexia: A Systematic Review and Meta-Analysis.Cannabis and cannabinoid research · 2021Pooled it
- Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways.Acta physiologica (Oxford, England) · 2020Pooled it
- Megestrol acetate for cachexia-anorexia syndrome. A systematic review.Journal of cachexia, sarcopenia and muscle · 2018Pooled it
- Effects of adjunct testosterone on cardiac morphology and function in advanced cancers: an ancillary analysis of a randomized controlled trial.BMC cancer · 2019Trial
- Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.Journal of cachexia, sarcopenia and muscle · 2019Trial
- Trial
- Trial
- ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study.Orphanet journal of rare diseases · 2015Trial
- The Growth and Trends in Cancer-Induced Cachexia Research: A Bibliometric and AI-Guided Visualization Analysis.Cancer reports (Hoboken, N.J.) · 2026Review
- Bone Loss, Osteoporosis, and Skeletal Fragility: Hidden Consequences of Cancer Cachexia.Cells · 2026Review
- Observational
- A cohort study investigating differences in skeletal muscle mitochondrial function between prostate cancer patients and healthy controls.BMC cancer · 2026Article
- Addressing gaps in cancer cachexia care among healthcare professionals at Uganda Cancer Institute.Scientific reports · 2026Article
- Article
- Cancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.Journal of cachexia, sarcopenia and muscle · 2026Article
- Does Cachexia Matter for Glioblastoma Multiforme?Cancers · 2026Article
155 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cachexia is a serious but underrecognised consequence of many chronic diseases. Its prevalence ranges from 5-15 % in end-stage chronic heart failure to 50-80 % in advanced cancer. Cachexia is also part of the terminal course of many patients with chronic kidney disease, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis. Mortality rates of patients with cachexia range from 10-15 % per year in COPD through 20-30 % per year in chronic heart failure and chronic kidney disease to 80 % in cancer. The condition is also associated with poor quality of life. In the industrialised world, the overall prevalence of cachexia (due to any disease and not necessarily associated with hospital admission) is growing and it currently affects around 1 % of the patient population, i.e. around 9 million people. It is also a significant health problem in other parts of the globe. Recently there have been advances in our understanding of the multifactorial nature of the condition, and particularly of the role of inflammatory mediators and the imbalance of anabolism and catabolism. Several promising approaches to treatment have failed to live up to the challenge of phase III clinical trials, but the ghrelin receptor agonist anamorelin seems to have fulfilled at least some early promise. Further advances are urgently needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.